SXTP 60 DEGREES PHARMACEUTICALS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1946563 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-2.8%
TTM net income YoY-4.7%
TTM EPS YoY95.7%
Revenue 3-yr CAGR115.4%
Net income 3-yr CAGR—
Margins
Gross margin24.1%
Operating margin-971.9%
Net margin-921.0%
FCF margin-906.9%
EBITDA margin-964.6%
Returns
ROE-316.7%
ROA-170.7%
ROIC (approx.)-1,197.4%
Asset turnover0.19x
Leverage & solvency
Liabilities / assets75.6%
Debt / equity0.18x
Current ratio1.17x
Interest coverage-1,207.18x
Cash quality & payout
Operating cash flow / net income0.97x
Accruals ratio-4.8%
Payout ratio—
Capex / revenue12.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $1.01M | $607,574 | $253,573 | $223,208 |
| Cost of revenue | $781,695 | $384,765 | $474,550 | $432,370 |
| Gross profit | $223,776 | $222,809 | -$220,977 | -$209,162 |
| R&D expense | $2.11M | $4.99M | $691,770 | $525,563 |
| SG&A expense | $6.28M | $5.03M | $4.24M | $1.30M |
| Operating income | -$7.76M | -$9.72M | -$5.15M | -$1.75M |
| Interest expense | $7,805 | $7,912 | $2.29M | $3.99M |
| Pretax income | -$7.37M | -$7.96M | -$3.81M | -$6.18M |
| Income tax | $0 | $0 | $250 | $500 |
| Net income | -$7.37M | -$7.95M | -$3.77M | -$6.18M |
| EBITDA | -$7.72M | -$9.70M | -$5.13M | -$1.72M |
| EPS (basic) | -11.73 | -74.17 | -59.18 | -2.61 |
| EPS (diluted) | -11.73 | -74.17 | -59.18 | -2.61 |
| Weighted avg. shares (diluted) | 670,211 | 113,665 | 66,314 | 2.37M |
| Banking | ||||
| Net interest income | — | — | $1.34M | -$4.43M |
| Balance sheet | ||||
| Cash & equivalents | $1.51M | $1.66M | $2.14M | $264,865 |
| Short-term investments | $1.24M | $1.73M | — | — |
| Receivables | $509,644 | $486,748 | $231,332 | $45,965 |
| Inventory | $656,924 | $442,764 | $466,169 | $518,578 |
| Current assets | $4.90M | $5.39M | $7.24M | $1.10M |
| PP&E, net | $246,365 | $149,808 | $57,761 | $21,300 |
| Intangibles | $224,361 | $157,084 | $227,258 | $164,255 |
| Total assets | $5.37M | $5.76M | $7.78M | $1.30M |
| Current liabilities | $1.85M | $1.66M | $2.84M | $23.92M |
| Short-term debt | $11,517 | $8,772 | $8,772 | — |
| Long-term debt | $144,003 | $147,119 | $150,000 | $1.11M |
| Total debt | $155,520 | $155,891 | $158,772 | $1.11M |
| Total liabilities | $1.99M | $1.80M | $2.99M | $25.45M |
| Shareholders' equity | $3.46M | $4.04M | $4.87M | -$23.58M |
| Net debt | -$1.35M | -$1.50M | -$1.98M | $844,918 |
| Shares outstanding | 1.16M | 141,749 | 96,847 | — |
| Cash flow statement | ||||
| Operating cash flow | -$6.85M | -$5.65M | -$4.54M | -$1.01M |
| Capital expenditure | $139,881 | $103,773 | $57,623 | — |
| Free cash flow | -$6.99M | -$5.75M | -$4.60M | — |
| Investing cash flow | $254,916 | -$1.89M | -$115,888 | -$60,133 |
| Financing cash flow | $6.44M | $7.05M | $6.47M | $1.22M |
| Depreciation & amortization | $43,324 | $11,726 | $21,162 | $27,648 |
| Stock-based compensation | $456,344 | $3.61M | $212,605 | $0 |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.